

JC10 Rec'd PCT/PTO 22 JAN 2002

FORM PTO-1390  
(REV. 9-2001)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

2488-1-002

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371**

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

**10/031685**

INTERNATIONAL APPLICATION NO.  
PCT/GB00/02791

INTERNATIONAL FILING DATE  
19 July 2000

PRIORITY DATE CLAIMED  
19 July 1999

TITLE OF INVENTION

**INHIBITOR PROTEINS**

APPLICANT(S) FOR DO/EO/US

Patricia Anne NUTTALL; and Guido Christiaan PAESEN

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☒ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☒ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☒ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). **UNEXECUTED**
10. ☒ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).


**Items 11 to 20 below concern document(s) or information included:**

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information: **Copy of International Search Report; Six (6) sheets; of Drawings (Figs. 1-6)**

EXPRESS MAIL CERTIFICATE NO.: EL 790334525 US DATE OF DEPOSIT: January 22, 2002

531 Rec'd PCT/A

22 JAN 2002

U.S. APPLICATION NO. (if known) <b>10/031689</b> PCT/GB00/02791		INTERNATIONAL APPLICATION NO. ATTORNEY'S DOCKET NUMBER <b>2488-1-002</b>	
21. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. . . . . <b>\$1040.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO . . . . . <b>\$890.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO . . . . . <b>\$740.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) . . . . . <b>\$710.00</b> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) . . . . . <b>\$100.00</b> <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		<b>CALCULATIONS PTO USE ONLY</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$ 890.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	56 - 20 =	36	x \$18.00
Independent claims	3 - 3 =	0	x \$84.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>		<b>\$ 1,818.00</b>	
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		+ \$ 909.00	
<b>SUBTOTAL =</b>		<b>\$ 909.00</b>	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$	
<b>TOTAL NATIONAL FEE =</b>		\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +		\$	
<b>TOTAL FEES ENCLOSED =</b>		<b>\$ 909.00</b>	
		<b>Amount to be refunded:</b>	\$
		<b>charged:</b>	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>909.00</u> to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>11-1153</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card</b> <b>information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.			
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</b>			
SEND ALL CORRESPONDENCE TO: <b>DAVID A. JACKSON</b> <b>KLAUBER &amp; JACKSON</b> 411 Hackensack Avenue Hackensack, New Jersey 07601 (201) 487-5800		 SIGNATURE David A. Jackson NAME 26,742 REGISTRATION NUMBER	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Patricia Anne NUTTALL; Guido Christiaan PAESEN  
APPLICATION NO. : PCT/GB00/02791  
FILED : 19 July 2000  
FOR : INHIBITOR PROTEINS

PRELIMINARY AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS  
BOX PCT  
WASHINGTON, D.C. 20231

Sir:

Prior to calculating the fees pursuant to the entry into the National Phase of the above-identified Application, please amend the Specification and Claims as follows:

**IN THE SPECIFICATION:**

Please amend the specification as follows:

Please replace the paragraph at Page 2, Lines 23-26, with the following

--According to a first aspect of the present invention there is provided a recombinant protein that exhibits significant sequence homology with the tick-derived protease inhibitor protein (TdPI) sequence given in Figure 1 (SEQ.ID. NO:2), an active fragment of said protein or a functional equivalent of said protein.--

Please replace the paragraph at Page 3 Lines 7-14, with the following

--Included in this aspect of the invention there is provided a protein comprising the sequence

identified herein as tick-derived protease inhibitor protein (TdPI), an active fragment thereof or a functional equivalent thereof. This sequence is given in accompanying Figure 1 (SEQ.ID.NO:2). This protein was identified as being encoded by a cDNA from a tick salivary gland library. The protein has a molecular weight of approximately 13.5 kDa and appears to belong to the family of Kunitz-type protease inhibitors. The sequence similarity with other members of this family such as aprotinin and inter-alpha-trypsin inhibitor is low, but the putative reactive centre and the position of the cysteines is to some extent conserved.--

Please replace the paragraphs at Page 8, Lines 20-22 and 23-29, respectively, with the following

--A cDNA encoding TdPI is disclosed herein by way of example and its sequence and the amino acid sequence it encodes are shown in Figure 1 (nucleotides (SEQ ID NO:1) and amino acids (SEQ ID NO:2) are given in their standard one letter abbreviations).

A preferred nucleic acid molecule according to the invention comprises a nucleotide sequence identical to or complementary to the sequence shown in Figure 1 (SEQ ID NO:1), or a sequence that is degenerate or substantially homologous therewith, or which hybridises with this sequence under non-stringent conditions, for instance 6 x SSC/50% formamide at room temperature, and washed under conditions of low stringency, for instance (2 x SSC room temperature or 2 x SSC, 42°C or, more preferably, binding under conditions of higher stringency, e.g. 2 x SSC, 65°C. (SSC = 0.15M NaCl, 0.015M sodium citrate, pH 7.2).--

Please replace the paragraphs at Page 10, lines 19-20 and 23-26, respectively, with the following:

--Figure 1 shows the cDNA sequence (SEQ ID NO:1) and inferred amino-acid sequence (SEQ ID NO:2) of TdPI-encoding clone 76-3.

Figure 3 shows an alignment of TdPI (SEQ ID NO:2) with Kunitz domains of the bovine

colostrum trypsin inhibitor (SEQ ID NO:3) (BovCol; Cechova, 1976), (bovine) aprotinin (SEQ ID NO:5) (Creighton & Charles, 1987), and the rat tissue factor pathway inhibitor (TFPI-2 (SEQ ID NO:4); only the second, factor Xa-inhibiting domain is shown; Enjyoji *et al.*, 1992).--

Please replace the paragraph from Page 12, Line 16 to Page 13, line2, with the following:

--Recombinant TdPI (rTdPI) was expressed as a histidine-tagged protein in *Spodoptera frugiperda* ovarian cells (SJ21; Invitrogen). The coding region of the TdPI cDNA was amplified by the polymerase chain reaction (PCR), using the forward primer

5'-GCAGGAGCTCGGCACGAG (SEQ ID NO:9)

and the reverse primer

5'-TATGGATCCCAGGTCCAGGCTCTGTTCCG (SEQ ID NO:10),

thereby adding a *Sac* I site upstream of the start codon, and replacing the stop codon with a *Bam* HI site. The PCR consisted of 20 cycles with a 30-second melting step (95°C) a 30-second primer-annealing step (50°C) and a 30-second extension step (72°C). The PCR product was ligated between the *Sac* I and *Bam* HI sites of the pAC129.1 transfer vector (Livingstone & Jones, 1989), which was modified so that a carboxyterminal Gly-Ile-(His)<sub>6</sub> tag was added to the expressed protein. Co-transfection of SJ21 cells with the transfer vector and baculovirus (BacPak6) and amplification of recombinant virus was as described by Kitts & Possee, 1993. rTdPI was expressed in TC100 medium (Gibco BRL) containing 10% foetal bovine serum (Sigma).--

Please replace the paragraph from Page 14, Lines 4-16 with the following:

--Figure 3 shows an alignment of TdPI (SEQ ID NO:2) with Kunitz domains of the bovine colostrum trypsin inhibitor (SEQ ID NO:3) (BovCol; Cechova, 1976), (bovine) aprotinin (SEQ ID NO:5) (Creighton & Charles, 1987), and the rat tissue factor pathway inhibitor (SEQ ID NO:4) (TFPI-2; only the second, factor Xa-inhibiting domain is shown; Enjyoji *et al.*, 1992). The Kunitz domains of the tick anticoagulant peptide TAP (SEQ ID NO:6) (Waxman *et al.*, 1990) and the two domains in ornithodorin (ornith1 (SEQ ID NO:7) and ornith2 (SEQ ID NO:8); Van de Locht *et al.*, 1996) are also included. The alignment of TdPI with the vertebrate Kunitz domains was created using GCG's "pileup" and "prettyplot" commands, choosing relatively low gap and length weights (1 and 0.03, respectively). The alignment was then modified, mainly by introducing extra gaps, so that the TAP and ornithodorin domains could be included. The modification was largely based on the alignment of the latter domains with aprotinin, as reported by Van de Locht *et al.*, 1996. The arrow indicates the PI residue of the aprotinin binding loop. The asterisks denote the cysteines involved in disulphide-bridge formation in traditional Kunitz domains.--

IN THE CLAIMS:

Please amend Claims 1, 3, 4, 7, 10-14, 16-24, 27, and 29-33 as follows:

1. (Amended) A recombinant protein that exhibits significant sequence homology with the tick-derived protease inhibitor protein (TdPI) sequence set forth in SEQ ID NO:2, an active fragment of said protein or a functional equivalent of said protein.
3. (Amended) A recombinant protein, protein fragment or functional equivalent according to claim 1 that contains one or more epitopes that can be used in the development of vaccines that target proteins that exhibit significant sequence homology with TdPI.
4. (Amended) A recombinant protein or protein fragment according to claim I, wherein said sequence homology is defined as 50% or more of the amino acids in the sequence being

completely conserved as identical residues if the protein is aligned with the sequence of SEQ ID NO:2, the alignments being obtained using GCG's bestfit command (gap creation penalty = 2.5; gap extension penalty = 0.5).

7. (Amended) A recombinant protein or protein fragment according to claim 1 comprising the TdPI sequence.

10. (Amended) A recombinant protein, protein fragment or functional equivalent according to claim 8 that contains one or more epitopes that can be used in the development of vaccines that target proteins that exhibit significant sequence homology with TdPI.

11. (Amended) A recombinant protein or protein fragment according to either of claims 1 or 8 that inhibits tryptase with a  $K_i$  of less than  $1 \times 10^{-6}$  M, preferably less than  $1 \times 10^{-7}$  M, more preferably less than  $2 \times 10^{-8}$  M, most preferably less than  $1 \times 10^{-9}$  M.

12. (Amended) A recombinant protein, protein fragment or functional equivalent according to either of claims 1 or 8 that inhibits catalytic tryptase activity.

13. (Amended) A recombinant protein, protein fragment or functional equivalent according to either of claims 1 or 8 which inhibits mast cell tryptase, preferably human mast cell tryptase.

14. (Amended) A recombinant protein, protein fragment or functional equivalent according to claim 1, that is derived from a tick.

16. (Amended) A recombinant protein, protein fragment or functional equivalent according to either of claims 1 or 8 that has been genetically or chemically fused to one or more peptides or polypeptides.

17. (Amended) A recombinant protein, protein fragment or functional equivalent according to either of claims 1 or 8 that is bound to a support, such as a resin.

18. (Amended) A pharmaceutical composition comprising a recombinant protein, protein fragment or functional equivalent according to either of claims 1 or 8, in conjunction with a pharmaceutically-acceptable carrier.

19. (Amended) A vaccine composition comprising a recombinant protein, protein fragment or functional equivalent according to either of claims 1 or 8, optionally in conjunction with an adjuvant.

20. (Amended) A process for the formulation of a pharmaceutical composition according to claim 19 comprising bringing said recombinant protein, protein fragment or functional equivalent into association with a pharmaceutically-acceptable carrier.

21. (Amended) A recombinant protein, protein fragment or functional equivalent according to either of claims 1 or 8 for use as a pharmaceutical.

22. (Amended) A method for the prevention or treatment of a disease in a subject, comprising administering to said subject an effective dose of a composition according to claim 18.

23. (Amended) A nucleic acid molecule encoding a recombinant protein, protein fragment or functional equivalent according to claim 1.

24. (Amended) A nucleic acid molecule having the sequence set forth in SEQ ID NO:1; which hybridises with said nucleotide sequence under stringent hybridisation conditions; or which encodes on expression a recombinant protein, protein fragment or functional equivalent as defined in claim 1.



27. (Amended) A host cell transformed or transfected with the vector of claim 25.

29. (Amended) A method of preparing a recombinant protein, protein fragment or functional equivalent, comprising expressing a vector according to claim 25 or claim 26 in a host cell and culturing said host cell under conditions where said recombinant protein, protein fragment or functional equivalent is expressed, and recovering said recombinant protein, protein fragment or functional equivalent thus produced.

30. (Amended) A method for the detection or quantification of tryptase in a sample to be tested, comprising contacting said sample with a kit comprising at least one recombinant protein, protein fragment or functional equivalent according to claim 1, and other reagents for detection.

31. (Amended) A method for the treatment of inflammation in humans or animals comprising administering a therapeutically effective amount of a recombinant protein, protein fragment or functional equivalent according to claim 1.

32. (Amended) A method of vaccinating a mammal against a disease, or of treating a mammal suffering from a disease, comprising administering a recombinant protein, protein fragment or functional equivalent according to claim 1 to a said mammal.

33. (Amended) A tryptase inhibitor comprising a protein or protein fragment selected from the group consisting of bovine colostrum trypsin inhibitor, the rat tissue factor pathway inhibitor (TFPI-2), the Kunitz domain of the tick anticoagulant peptide TAP and the two domains in omithodorin.

Please add the following new Claims 34-39 as follows:

--Claim 34. A method for the prevention or treatment of a disease in a subject, comprising

administering to said subject an effective dose of a composition according to claim 19. --

--Claim 35. A host cell transformed or transfected with the vector of claim 26.--

--36. A method for the depletion or removal of tryptase from a food product or from a cell culture comprising contacting the food product or cell culture with a quantity of a recombinant protein, protein fragment or functional equivalent according to claim 1.--

--37. The method of claim 36 wherein said recombinant protein, protein fragment or functional equivalent is bound to a support.--

--38. An anti-tryptase agent comprising a recombinant protein, protein fragment or functional equivalent according to claim 1.--

--39. An anti-inflammatory agent comprising a recombinant protein, protein fragment or functional equivalent according to claim 1.--

REMARKS

The above amendment is made to place the present application into close conformity with U.S. practice and to complete certain informalities that are prerequisite to entry into the National Phase before the U.S. Patent and Trademark Office. A Sequence Listing in conformity with U.S. practice is submitted herewith together with a computer-readable copy and the necessary Declaration confirming that both are identical to each other. No new matter is inserted hereby, as the Sequence Listing in question corresponds in substance to the listing that was present in the parent International Application.

Also, appropriate amendments have been made in the Specification where reference to the sequences by other than sequence listing identification, is present. Thus, the paragraphs set forth in the amendment to the Specification identify those passages where reference to a Sequence Listing appears necessary.


Lastly, the Claims have been amended to include reference to the Sequence Listing, where appropriate. Likewise, the claims have been revised to place them into greater conformity with U.S. practice by eliminating improper multiple dependencies and the redrafting of certain claims, such as, for example, the revision of Claims 30, 31 and 33 to convert them from use claims, and the presentation of new Claims 34-39 to cover appropriately worded methods, both diagnostic and therapeutic.

The Claims presented by this amendment are believed to be in proper form for U.S. practice, and entry and favorable consideration thereof are requested.

PATENT  
2488-1-002

Entry of the foregoing amendments and early and favorable processing in the National Phase before the United States Patent and Trademark Office is courteously solicited.

Respectfully submitted,



DAVID A. JACKSON  
Attorney for Applicant(s)  
Registration No. 26,742

KLAUBER & JACKSON  
411 Hackensack Avenue  
Hackensack, NJ 07601  
(201) 487-5800

20071005 10:03:00

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION:**

The Specification has been amended as follows:

Please replace the paragraph at Page 2, Lines 23-26, with the following

--According to a first aspect of the present invention there is provided a recombinant protein that exhibits significant sequence homology with the tick-derived protease inhibitor protein (TdPI) sequence given in Figure 1 (SEQ.ID. NO:2), an active fragment of said protein or a functional equivalent of said protein.--

Please replace the paragraph at Page 3 Lines 7-14, with the following

--Included in this aspect of the invention there is provided a protein comprising the sequence identified herein as tick-derived protease inhibitor protein (TdPI), an active fragment thereof or a functional equivalent thereof. This sequence is given in accompanying Figure 1 (SEQ.ID.NO:2). This protein was identified as being encoded by a cDNA from a tick salivary gland library. The protein has a molecular weight of approximately 13.5 kDa and appears to belong to the family of Kunitz-type protease inhibitors. The sequence similarity with other members of this family such as aprotinin and inter-alpha-trypsin inhibitor is low, but the putative reactive centre and the position of the cysteines is to some extent conserved.--

Please replace the paragraphs at Page 8, Lines 20-22 and 23-29, respectively, with the following

--A cDNA encoding TdPI is disclosed herein by way of example and its sequence and the amino acid sequence it encodes are shown in Figure 1 (nucleotides (SEQ ID NO:1) and amino acids (SEQ ID NO:2) are given in their standard one letter abbreviations).

A preferred nucleic acid molecule according to the invention comprises a nucleotide sequence identical to or complementary to the sequence shown in Figure 1 (SEQ ID NO:1), or a sequence that is degenerate or substantially homologous therewith, or which hybridises with this sequence under non-stringent conditions, for instance 6 x SSC/50% formamide at room temperature, and washed under conditions of low stringency, for instance (2 x SSC room temperature or 2 x SSC, 42°C or, more preferably, binding under conditions of higher stringency, e.g. 2 x SSC, 65°C. (SSC = 0.15M NaCl, 0.015M sodium citrate, pH 7.2).--

Please replace the paragraphs at Page 10, lines 19-20 and 23-26, respectively, with the following:

--Figure 1 shows the cDNA sequence (SEQ ID NO:1) and inferred amino-acid sequence (SEQ ID NO:2) of TdPI-encoding clone 76-3.

Figure 3 shows an alignment of TdPI (SEQ ID NO:2) with Kunitz domains of the bovine colostrum trypsin inhibitor (SEQ ID NO:3) (BovCol; Cechova, 1976), (bovine) aprotinin (SEQ ID NO:5) (Creighton & Charles, 1987), and the rat tissue factor pathway inhibitor (TFPI-2 (SEQ ID NO:4); only the second, factor Xa-inhibiting domain is shown; Enjyoji *et al.*, 1992).--

Please replace the paragraph from Page 12, Line 16 to Page 13, line2, with the following:

--Recombinant TdPI (rTdPI) was expressed as a histidine-tagged protein in *Spodoptera frugiperda* ovarian cells (SJ21; Invitrogen). The coding region of the TdPI cDNA was amplified by the polymerase chain reaction (PCR), using the forward primer

5'-GCAGGAGCTCGGCACGAG (SEQ ID NO:9)

and the reverse primer

5'-TATGGATCCCAGGTCCAGGCTCTGTTCCG (SEQ ID NO:10),

thereby adding a *Sac* I site upstream of the start codon, and replacing the stop codon with a *Bam* HI site. The PCR consisted of 20 cycles with a 30-second melting step (95°C) a 30-second primer-annealing step (50°C) and a 30-second extension step (72°C). The PCR product was ligated between the *Sac* I and *Bam* HI sites of the pAC129.1 transfer vector (Livingstone & Jones, 1989), which was modified so that a carboxyterminal Gly-Ile-(His)<sub>6</sub> tag was added to the expressed protein. Co-transfection of SJ21 cells with the transfer vector and baculovirus (BacPak6) and amplification of recombinant virus was as described by Kitts & Possee, 1993. rTdPI was expressed in TC100 medium (Gibco BRL) containing 10% foetal bovine serum (Sigma).--

Please replace the paragraph from Page 14, Lines 4-16 with the following:

--Figure 3 shows an alignment of TdPI (SEQ ID NO:2) with Kunitz domains of the bovine colostrum trypsin inhibitor (SEQ ID NO:3) (BovCol; Cechova, 1976), (bovine) aprotinin (SEQ ID NO:5) (Creighton & Charles, 1987), and the rat tissue factor pathway inhibitor (SEQ ID NO:4) (TFPI-2; only the second, factor Xa-inhibiting domain is shown; Enjyoji *et al.*, 1992). The Kunitz domains of the tick anticoagulant peptide TAP (SEQ ID NO:6) (Waxman *et al.*, 1990) and the two domains in ornithodorin (ornith1 (SEQ ID NO:7) and ornith2 (SEQ ID NO:8); Van de Locht *et al.*, 1996) are also included. The alignment of TdPI with the vertebrate Kunitz domains was created using GCG's "pileup" and "prettyplot" commands, choosing relatively low gap and length weights (1 and 0.03, respectively). The alignment was then modified, mainly by introducing extra gaps, so that the TAP and ornithodorin domains could be included. The modification was largely based on the alignment of the latter domains with aprotinin, as reported by Van de Locht *et al.*, 1996. The arrow indicates the PI residue of the aprotinin binding loop. The asterisks denote the cysteines involved in disulphide-bridge formation in traditional Kunitz domains.--

**IN THE CLAIMS:**

Claims 1, 3, 4, 7, 10-14, 16-24, 27, and 29-33 have been amended as follows:

1. (Amended) A recombinant protein that exhibits significant sequence homology with the tick-derived protease inhibitor protein (TdPI) sequence [given in Figure 1] set forth in SEQ ID NO:2, an active fragment of said protein or a functional equivalent of said protein.
3. (Amended) A recombinant protein, protein fragment or functional equivalent according to [either of] claim[s] I[-2] that contains one or more epitopes that can be used in the development of vaccines that target proteins that exhibit significant sequence homology with TdPI.
4. (Amended) A recombinant protein or protein fragment according to claim I, wherein said sequence homology is defined as 50% or more of the amino acids in the sequence being completely conserved as identical residues if the protein is aligned with the sequence of [Figure 1] SEQ ID NO:2, the alignments being obtained using GCG's bestfit command (gap creation penalty = 2.5; gap extension penalty = 0.5).
7. (Amended) A recombinant protein or protein fragment according to [any one of claims 1-6] claim 1 comprising the TdPI sequence.
10. (Amended) A recombinant protein, protein fragment or functional equivalent according to claim 8 [or claim 9] that contains one or more epitopes that can be used in the development of vaccines that target proteins that exhibit significant sequence homology with TdPI.
11. (Amended) A recombinant protein or protein fragment according to either [any one] of claims I[-10] or 8 that inhibits tryptase with a  $K_i$  of less than  $1 \times 10^{-6}$  M, preferably less than  $1 \times 10^{-7}$  M, more preferably less than  $2 \times 10^{-8}$  M, most preferably less than  $1 \times 10^{-9}$  M.



12. (Amended) A recombinant protein, protein fragment or functional equivalent according to either of [any one of the] claims 1[-11] or 8 that inhibits catalytic trypsin activity.

13. (Amended) A recombinant protein, protein fragment or functional equivalent according to either of [any one of] claims 1[-12] or 8 which inhibits mast cell trypsin, preferably human mast cell trypsin.

14. (Amended) A recombinant protein, protein fragment or functional equivalent according to [any one of the preceding claims] claim 1, that is derived from a tick.

16. (Amended) A recombinant protein, protein fragment or functional equivalent according to [any one of the preceding claims] either of claims 1 or 8 that has been genetically or chemically fused to one or more peptides or polypeptides.

17. (Amended) A recombinant protein, protein fragment or functional equivalent according to [any one of the preceding claims] either of claims 1 or 8 that is bound to a support, such as a resin.

18. (Amended) A pharmaceutical composition comprising a recombinant protein, protein fragment or functional equivalent according to [any one] either of claims 1[-17] or 8, in conjunction with a pharmaceutically-acceptable carrier.

19. (Amended) A vaccine composition comprising a recombinant protein, protein fragment or functional equivalent according to [any one] either of claims 1[-15] or 8, optionally in conjunction with an adjuvant.

20. (Amended) A process for the formulation of a pharmaceutical composition according to claim 19 comprising bringing [a] said recombinant protein, protein fragment or functional

equivalent [according to any one of claims 1-15] into association with a pharmaceutically-acceptable carrier.

21. (Amended) A recombinant protein, protein fragment or functional equivalent according to [any one] either of claims 1 [to 15] or 8 for use as a pharmaceutical.

22. (Amended) A method for the prevention or treatment of a disease in a subject, comprising administering to said subject an effective dose of a composition according to claim 18 [or claim 19].

23. (Amended) A nucleic acid molecule encoding a recombinant protein, protein fragment or functional equivalent according to [any one of claims 1-16] claim 1.

24. (Amended) A nucleic acid molecule[: ] having the sequence [given in Figure 1] set forth in SEQ ID NO:1; which hybridises with said nucleotide sequence under stringent hybridisation conditions; or which encodes on expression a recombinant protein, protein fragment or functional equivalent as defined in [any one of claims 1-16] claim 1.

27. (Amended) A host cell transformed or transfected with the vector of claim 25 [or claim 26].

29. (Amended) A method of preparing a recombinant protein, protein fragment or functional equivalent [according to any one of claims 1 to 16], comprising expressing a vector according to claim 25 or claim 26 in a host cell and culturing said host cell under conditions where said recombinant protein, protein fragment or functional equivalent is expressed, and recovering said recombinant protein, protein fragment or functional equivalent thus produced.

30. (Amended) [Use of a recombinant protein, protein fragment or functional equivalent according to any one of claims 1-17 for:] A method for the detection or quantification of

tryptase[; for the depletion or removal of tryptase from a food product or from a cell culture; as an anti-tryptase agent; or as an anti-inflammatory drug] in a sample to be tested, comprising contacting said sample with a kit comprising at least one recombinant protein, protein fragment or functional equivalent according to claim 1, and other reagents for detection.

31.(Amended) [Use of a recombinant protein, protein fragment or functional equivalent according to any one of claims 1 to 16 in the manufacture of a medicament] A method for the treatment of inflammation in humans or animals comprising administering a therapeutically effective amount of a recombinant protein, protein fragment or functional equivalent according to claim 1.

32. (Amended) A method of vaccinating a mammal against a disease, or of treating a mammal suffering from a disease, comprising administering a recombinant protein, protein fragment or functional equivalent according to [any one of claims 1 to 16] claim 1 to a said mammal.

33. (Amended) [Use of] A tryptase inhibitor comprising a protein or protein fragment selected from the group consisting of bovine colostrum trypsin inhibitor, the rat tissue factor pathway inhibitor (TFPI-2), the Kunitz domain of the tick anticoagulant peptide TAP and the two domains in omithodorin [as a tryptase inhibitor].

The following new Claims 34, 35, 36, 37, 38 and 39 have been added.

--Claim 34. A method for the prevention or treatment of a disease in a subject, comprising administering to said subject an effective dose of a composition according to claim 19. --

--Claim 35. A host cell transformed or transfected with the vector of claim 26.--

--36. A method for the depletion or removal of tryptase from a food product or from a cell culture comprising contacting the food product or cell culture with a quantity of a recombinant protein, protein fragment or functional equivalent according to claim 1. --

--37. The method of claim 36 wherein said recombinant protein, protein fragment or functional equivalent is bound to a support.--

--38. An anti-tryptase agent comprising a recombinant protein, protein fragment or functional equivalent according to claim 1.--

--39. An anti-inflammatory agent comprising a recombinant protein, protein fragment or functional equivalent according to claim 1. --

## INHIBITOR PROTEINS

The present invention relates to novel proteins that have been identified in ticks. These proteins may be used as components of vaccines, as inhibitors of mast cell tryptase (hereafter referred to as MCT), in the detection of mast cells and in the isolation and  
5 purification of MCT. The invention also relates to the control of diseases and injury caused by parasites in animals and humans and to the use of the proteins of the invention in the treatment of diseases and allergies.

All documents mentioned in the text and listed at the end of this description are incorporated herein by reference.

10 Human MCT is an endoprotease that is stored in the secretory granules of mast cells and, upon activation, is released from the mast cells as a tetramer that is stabilised by heparin. Removal of heparin leads to the dissociation of the tryptase complex into enzymatically inactive monomers (Schwartz, 1994).

Tryptase is the principal protein mediator component of human mast cell granules,  
15 accounting for over 20% of the total cellular protein (Schwartz, 1994). MCT is a specific marker of mast cells, allowing for their differentiation from basophils.

Mast cells are found in many tissues but are present in greater numbers along the epithelial linings of the body, such as the skin, respiratory tract and gastrointestinal tract. Mast cells are often located in the proximity of small blood vessels. They are involved in a variety of  
20 physiological and pathophysiological states, including acute inflammation, immediate hypersensitivity, delayed-type hypersensitivity, cell growth regulation, defence against neoplasia and the sensation of pain and itch (Liang *et al.*, 1998). Mast cells are also implicated in chronic inflammatory states and are involved in neuroimmune interactions (Leon *et al.*, 1994).

25 Mast cell tryptase is an important inflammatory response mediator. Experiments (mainly performed *in vitro*) suggest it plays important roles in diseases such as asthma, psoriasis, interstitial lung disease, rheumatoid arthritis, gingivitis and periodontitis. Mast cell tryptase has also been implicated in tumorigenesis and angiogenesis, due to its potential to activate pro-urokinase and the matrix metalloproteinase pro-stromelysin. Tryptase-like enzymes

have also been described to take part in the activation and internalisation of pathogenic viruses, such as influenza virus, Sendai virus and human immunodeficiency virus (Pohlig *et al.*, 1996).

Human tryptase is inhibited by small molecular weight substances (e.g. leupeptin and diisopropyl fluorophosphate). Divalent cations, such as calcium, and benzamidine and its derivatives are competitive inhibitors of human mast cell tryptase (Schwartz, 1994). However, human tryptase, unlike most other serine esterases, is not inhibited by classical inhibitors of serine proteases, such as aprotinin and soybean trypsin inhibitor. Endogenous inhibitors that target the catalytic sites of mast cell tryptase have yet to be reported. Human tryptase activity is inhibited by lactoferrin and myeloperoxidase (both neutrophil-derived) and by antithrombin-III, all of which antagonise the glycosaminoglycans (heparin or chondroitin sulfate) that stabilise the MCT tetramer (Alter *et al.*, 1990; Cregar *et al.*, 1999; Elrod *et al.*, 1997).

A leech-derived inhibitor of human tryptase (LDPI) has been previously described. A recombinant form of this Kazal-type protein has been found to inhibit efficiently 2 of the 4 catalytic sites of the tetrameric tryptase (Stubbs *et al.*, 1997; Auerswald *et al.*, 1994; Mühlhahn *et al.*, 1994; Sommerhoff *et al.*, 1994).

Due to the known importance of MCT in mammalian disease and in the allergic response, there is a clear need for highly specific and effective inhibitors of this protein. A novel protein has now been discovered in a tick species that is capable of inhibiting the activity of human mast cell tryptase.

#### Summary of the invention

According to a first aspect of the present invention there is provided a recombinant protein that exhibits significant sequence homology with the tick-derived protease inhibitor protein (TdPI) sequence given in Figure 1, an active fragment of said protein or a functional equivalent of said protein.

As used herein, the term "significant sequence homology" is meant to include all proteins that share a common function with TdPI and that exhibit common sequence homology or homology between motifs that are present in the polypeptide sequences. "Significant" overall homology refers to 50% or more of the amino acids in the sequence being completely

conserved as identical residues if the homologous protein is aligned with the sequence of TdPI. Preferably, the alignments are obtained using GCG's bestfit command (gap creation penalty = 2.5; gap extension penalty = 0.5)(Genetics-Computer-Group, 1994).

Preferably, the degree of homology is at least 60% across the entire length of the protein. More

5 preferably, the degree of homology is at least 70%, even more preferably 75%, most preferably 80% or more.

Included in this aspect of the invention there is provided a protein comprising the sequence identified herein as tick-derived protease inhibitor protein (TdPI), an active fragment thereof or a functional equivalent thereof. This sequence is given in accompanying Figure

10 1. This protein was identified as being encoded by a cDNA from a tick salivary gland library. The protein has a molecular weight of approximately 13.5 kDa and appears to belong to the family of Kunitz-type protease inhibitors. The sequence similarity with other members of this family such as aprotinin and inter-alpha-trypsin inhibitor is low, but the putative reactive centre and the position of the cysteines is to some extent conserved.

15 The term "functional equivalent" is used herein to describe proteins that have an analogous function to the TdPI protein, either in inhibiting tryptase or in possessing one or more epitopes that can be used in the development of vaccines that target proteins that exhibit significant sequence homology with TdPI. The term "functional equivalent" also refers to molecules that are structurally similar to the TdPI protein identified herein or that contain similar or identical  
20 tertiary structure. This term also includes protein fragments that retain the ability to inhibit tryptase, preferably human mast cell tryptase.

The analogous function in inhibiting tryptase is preferably directed against the catalytic activity of tryptase, preferably mast cell tryptase, more preferably human mast cell tryptase, is characterised by a  $K_i$  of less than  $1\mu\text{M}$ , more preferably  $100\text{nM}$ , even more preferably  
25  $20\text{nM}$ , even more preferably less than  $10\text{nM}$ , most preferably less than  $1\text{nM}$ , as assessed using any standard tryptase inhibition assay, such as that described herein (see section entitled "Protease inhibitions assays" in the Examples below).

Alternatively, or in addition to possessing inhibitory activity against tryptase, "functional equivalent" is used herein to describe proteins that contain epitopes which can be used in  
30 the development of vaccines against the proteins of the invention. Such functional

equivalents, and also fragments containing suitable epitopes, may be used to develop vaccines directed against blood-feeding parasites, that target members of the TdPI protein family. Functional equivalents may of course be made more or less immunogenic than the corresponding wild type protein or protein fragment in order to suit a desired application. By

5 "wild type" is meant the naturally-occurring genotype that is characteristic of most members of a species. If the proteins are to be used in a vaccination regime to induce host resistance to parasite proteins, then the molecules may be modified so as to enhance their immunogenicity. They will thus be more likely to elicit an immune response in the vaccinated host.

Functional equivalents of the proteins of the invention will include single or multiple amino-

10 acid substitution(s), addition(s), insertion(s) and/or deletion(s) from the wild type protein sequence and substitutions of chemically-modified amino acids that do not affect the function or activity of the protein in an adverse manner. This term is also intended to include natural biological variants (e.g. allelic variants or geographical variations within all the different species from which the wild type proteins are derived).

15 "Active" fragments are those that either inhibit tryptase, preferably human mast cell tryptase, and/or contain one or more epitopes that can be used in the development of vaccines against the proteins of the present invention. These biological properties are described above.

Preferably, the proteins of this aspect of the invention are derived from blood-feeding ectoparasites, such as mosquitoes or leeches, or from venomous animals such as spiders,

20 scorpions or snakes. More preferably, the proteins are derived from ticks, most preferably Ixodid ticks such as *Rhipicephalus appendiculatus*.

According to a second aspect of the invention there is provided a recombinant protein derived from a blood-feeding arthropod ectoparasite that inhibits tryptase, an active fragment thereof, or a functional equivalent thereof. Preferably, the recombinant protein is

25 derived from a tick, most preferably an Ixodid tick such as *Rhipicephalus appendiculatus*. The activity of these molecules in inhibiting the catalytic activity of tryptase, preferably mast cell tryptase, more preferably human mast cell tryptase, is characterised by a  $K_i$  of less than  $1\mu\text{M}$ , more preferably  $100\text{nM}$ , more preferably  $20\text{nM}$ , even more preferably less than  $10\text{nM}$ , most preferably  $1\text{nM}$  or less.



Derivatives of the proteins of the above-described aspects of the invention are included as embodiments of the invention. Such derivatives may include an additional protein or polypeptide fused at its amino- or carboxy-terminus or added internally. The purpose of the additional polypeptide may be to aid detection, expression, separation or purification of the protein or may be to lend the protein additional properties as desired. Examples of potential fusion partners include  $\beta$ -galactosidase, glutathione-S-transferase, luciferase, a polyhistidine tag, a T7 polymerase fragment and a secretion signal peptide.

The proteins of the present invention can be prepared using known techniques of molecular biology and protein chemistry. Protein fragments may be prepared by chemical synthesis, a technique that is especially useful for the generation of short peptides derived from the full length protein sequence, for use as immunogens.

The proteins of the invention may be prepared in recombinant form by expression in a host cell. Such expression methods are well known to those of skill in the art and many are described in detail by Sambrook *et al*, 1989, and Fernandez & Hoeffler, 1998.

A third aspect of the invention provides for the use of the proteins, protein fragments and functional equivalents of the invention to inhibit a tryptase, such as mast cell tryptase, in mammals, thereby to regulate its action and to control its pathological effects. Such molecules may also be used to inhibit trypsin, plasmin and, to a lesser degree, tissue kallikrein.

The invention also includes the use of the above-described proteins, protein fragments and functional equivalents as anti-inflammatory agents. Preferably, these molecules are provided as a pharmaceutical composition including an inert carrier. The protein, protein fragment or functional equivalent may constitute the sole active component of the composition or can form part of a therapeutic package, such as a component of creams for topical administration to insect, snake or scorpion bites, or to skin affected by dermatitis. It may also be used as a carrier molecule for tryptase and tryptase-related compounds, in creams, oils, powders or pills, to provide slow release of the bound components.

The invention also comprises the use of the proteins, protein fragments and functional equivalents of the invention for the quantification of tryptase levels, preferably human mast cell tryptase levels, for example, in blood, nasal lavage fluid, tissues or food products. This

may be as part of a kit that comprises one or more proteins, protein fragments or functional equivalents of the invention, together with means of detection (for example radiolabeled tryptase, antibodies, enzymes such as alkaline phosphatases, peroxidases and luciferases) that allow the accurate quantification of tryptase in the sample to be tested. Such kits may  
5 resemble radioimmunoassay or ELISA kits, with the proteins of the invention acting as binding molecules, rather than antibodies directed against tryptase or against tryptase-related molecules. One aspect of the present invention comprises such kits incorporating the molecules of the present invention.

The proteins, protein fragments and functional equivalents of the invention can also be used  
10 for the detection of cells carrying tryptase, and in particular for the detection of mast cells. Any technique common to the art may be used in such a detection method and may comprise immunocytochemical and histological techniques, in which the protein, protein fragment or functional equivalent is used in combination with antisera (such as anti-TdPI antisera), or in which the molecule is directly coupled to a label or dye, such as FITC. An  
15 entire protein may be used, or simply an active binding fragment in order to detect substrate. In another embodiment, the wild type protein may be fused either genetically or synthetically to another protein such as an alkaline phosphatase, luciferase or peroxidase in order to facilitate its detection. Other methods to detect tryptase-containing cells or samples may involve blotting techniques (Towbin *et al*, 1979), gel retardation, affinity  
20 chromatography, or any of the other suitable methods that are used in the art.

The invention also comprises the use of the proteins, protein fragments and functional equivalents of the present invention bound to a support to remove, purify, isolate or extract tryptase, for instance from body tissues, blood or food products. The support may comprise any suitable inert material and includes gels, magnetic and other beads, microspheres,  
25 binding columns and resins.

The present invention also includes the use of the proteins, protein fragments and functional equivalents of the invention as tools in the study of inflammation, inflammation-related processes or other physiological processes involving tryptase. These molecules may also be used as tools to study further the characteristics and functions of MCT itself. For example,  
30 the molecules may be used for tryptase inhibition or depletion in cell cultures or in inflamed animal tissues, in order to study the importance of tryptase in these systems.

Metazoan parasites, particularly arthropods and helminths, are also sources of infectious diseases and other injurious effects that have major impacts in human and veterinary medicine. Control of arthropod and helminth parasites currently relies primarily on the use of chemicals such as acaricides and antihelmintics. Attempts have been made to use immunological means of control through the use of vaccine technology. There has been some success in identifying certain protective antigens as potential vaccine candidates, but only a few have as yet come to commercial fruition, most notably for the cattle lungworm *Dictyocaulus viviparus* and the cattle tick *Boophilus microplus*. Despite these developments, there is a continuing need for metazoan parasite vaccines and in particular for a vaccine which may be used across a broad range of arthropod and/or helminth genera.

The present invention therefore also provides for the use of the proteins, protein fragments and functional equivalents of the invention as immunogens for use as metazoan parasite vaccines and in particular as protective immunogens in the control of diseases caused by arthropod and other metazoan parasites. Suitable candidates for vaccination include domesticated animals such as cattle, goats, sheep, dogs, cats and other animals which require protection against metazoan parasites, especially ticks. The vaccine may include certain compounds for use as adjuvants. Suitable adjuvants are well known in the art and include oil-in-water emulsion formulations, saponin adjuvants, Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA), cytokines, and other substances that act as immunostimulating agents to enhance the effectiveness of the composition.

According to a still further aspect of the present invention, there is provided a method of vaccinating a mammal against a disease or condition, comprising administering to a mammal a protein, protein fragment or functional equivalent according to the above-described aspects of the invention whose expression is associated with the disease or condition.

A further aspect of the invention provides a method of treating a mammal suffering from a disease or a condition such as asthma, psoriasis, an interstitial lung disease, rheumatoid arthritis, gingivitis, peridontitis, an allergic reaction, cancer or any other tryptase-mediated condition, comprising administering to said mammal a protein, protein fragment or functional equivalent according to the above-described aspects of the invention in a therapeutically-effective amount, optionally in conjunction with a pharmaceutically-acceptable carrier.

According to a further aspect of the present invention there is provided an immunogenic composition comprising a protein, protein fragment or functional equivalent of the above-described aspects of the invention in conjunction with a pharmaceutically-acceptable carrier.

Pharmaceutically-acceptable carriers include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolised macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes) and inactive virus particles. Such carriers are well known to those of skill in the art. The composition may be used as a vaccine and may thus optionally comprise an immunostimulating agent (adjuvant) for instance an adjuvant as referred to above. According to a further aspect of the invention, there is provided a process for the formulation of a vaccine composition comprising bringing a protein, protein fragment or functional equivalent according to the above-described aspects of the invention into association with a pharmaceutically-acceptable carrier, optionally with an adjuvant.

According to a further aspect of the invention there is provided a nucleic acid molecule comprising a nucleotide sequence encoding a protein, protein fragment or functional equivalent of the above-described aspects of the invention. Such molecules include single- or double-stranded DNA, cDNA and RNA, as well as synthetic nucleic acid species. Preferably, the nucleic acid sequences comprise DNA.

A cDNA encoding TdPI is disclosed herein by way of example and its sequence and the amino acid sequence it encodes are shown in Figure 1 (nucleotides and amino acids are given in their standard one letter abbreviations).

A preferred nucleic acid molecule according to the invention comprises a nucleotide sequence identical to or complementary to the sequence shown in Figure 1, or a sequence that is degenerate or substantially homologous therewith, or which hybridises with this sequence under non-stringent conditions, for instance 6 x SSC/50% formamide at room temperature, and washed under conditions of low stringency, for instance (2 x SSC room temperature or 2 x SSC, 42°C or, more preferably, binding under conditions of higher stringency, e.g. 2 x SSC, 65°C. (SSC = 0.15M NaCl, 0.015M sodium citrate, pH 7.2).

Preferably, said nucleic acid sequences display at least 60% identity to the cDNA encoding TdPI, or DNA sequences of which the translation product (either a partial stretch or the complete translation product) displays at least 60% or more identity with the TdPI sequence, when aligned, preferably using GCG's bestfit command (gap creation penalty = 5 2.5; gap extension penalty = 0.5) (Genetics Computer Group, 1994).

The invention also includes cloning and expression vectors containing the DNA sequences of this aspect of the invention. Such expression vectors may incorporate the appropriate transcriptional and translational control sequences, for example enhancer elements, promoter-operator regions, termination stop sequences, mRNA stability sequences, start 10 and stop codons or ribosomal binding sites, linked in frame with the nucleic acid molecules of the invention.

Additionally, it may be convenient to cause the recombinant protein to be secreted from certain hosts. Accordingly, further components of such vectors may include nucleic acid sequences encoding secretion signalling and processing sequences.

15 Vectors according to the invention include plasmids and viruses (including both bacteriophage and eukaryotic viruses), as well as other linear or circular DNA carriers, such as those employing transposable elements or homologous recombination technology. Many such vectors and expression systems are well known and documented in the art (Fernandez & Hoeffler, 1998). Particularly suitable viral vectors include baculovirus-, adenovirus- and 20 vaccinia virus-based vectors.

Suitable hosts for recombinant expression include commonly-used prokaryotic species, such as *E. coli*, or eukaryotic yeasts that can be made to express high levels of recombinant proteins and that can easily be grown in large quantities. Mammalian cell lines grown *in vitro* are also suitable, particularly when using virus-driven expression systems. Another 25 suitable expression system is the baculovirus expression system that involves the use of insect cells as hosts. An expression system may also constitute host cells that have the encoding DNA incorporated into their genome. Proteins, or protein fragments may also be expressed *in vivo*, for example in insect larvae or in mammalian tissues.

A variety of techniques are known and may be used to introduce the vectors according to 30 the present invention into prokaryotic or eukaryotic cells. Suitable transformation or

transfection techniques are well described in the literature (Sambrook *et al.*, 1989; Ausubel *et al.*, 1991; Spector, Goldman & Leinwald, 1998). In eukaryotic cells, expression systems may either be transient (e.g. episomal) or permanent (chromosomal integration) according to the needs of the system.

- 5 Nucleic acid molecules according to the present invention may also be used to create transgenic animals, particularly rodent animals. This may be done locally by modification of somatic cells, or by germ line therapy to incorporate heritable modifications.

The invention also includes transformed or transfected prokaryotic or eukaryotic host cells, or transgenic organisms containing a nucleic acid molecule as defined above.

- 10 A further aspect of the invention provides a method for preparing a protein, protein fragment or functional equivalent of the invention, as defined above, which comprises culturing a host cell containing a nucleic acid molecule according to the invention under conditions whereby said protein is expressed and recovering said protein thus produced.

- Various aspects and embodiments of the present invention will now be described in more detail by way of example, with particular reference to a protein isolated from the tick, *Rhipicephalus appendiculatus*. It will be appreciated that modification of detail may be made without departing from the scope of the invention.
- 15

#### **Brief description of figures**

- Figure 1 shows the cDNA sequence and inferred amino-acid sequence of TdPI-encoding clone 76-3.
- 20

Figure 2 shows a 15% SDS-polyacrylamide gel showing rTdPI, purified by means of metal-affinity chromatography and cation exchange.

- Figure 3 shows an alignment of TdPI with Kunitz domains of the bovine colostrum trypsin inhibitor (BovCol; Cechova, 1976), (bovine) aprotinin (Creighton & Charles, 1987), and the rat tissue factor pathway inhibitor (TFPI-2; only the second, factor Xa-inhibiting domain is shown; Enjyoji *et al.*, 1992).
- 25

Figure 4 shows a diagram showing the relatively weak inhibitory activity of rTdPI on tissue kallikrein.

Figure 5 shows the activities of plasmin (left) and trypsin (right) in the presence of increasing amounts of rTdPI as determined by measuring peptide release from resorufin-labelled casein.

Figure 6 shows the inhibition of recombinant human tryptase (Promega) with TdPI.

- 5 Figure 7 shows a 1.5% agarose gel showing the RT-PCR products obtained with whole-body extracts from larvae (L) and nymphs (N), and with salivary gland extracts from adult, *R. appendiculatus* males and females.

## EXAMPLES

### 10 Ticks

Ticks were reared according to Jones *et al.*, 1988. All three developmental stages of *R. appendiculatus* were fed on Dunkin Hartley guinea pigs. When not feeding, all ticks were maintained at 21 to 26°C and 85% relative humidity.

### cDNA

- 15 Clone 76, containing the TdPI cDNA, was one of several clones randomly picked from a *R. appendiculatus* salivary gland expression library in Lambda Zap II (Stratagene), which was constructed with mRNA from ticks that had been feeding on Dunkin Hartley guinea pigs for 2 days (Paesen & Nuttall, 1996). Phagemid was excised *in vivo* and used to generate double-stranded pBluescript SK(-) plasmid in XL1-Blue cells (Short *et al.*, 1988). Plasmid  
20 was purified from overnight cultures (Goode & Feinstein, 1992) and alkali-denatured (Mierendorf & Pfeffer, 1987) before sequencing according to Sanger & Coulson, 1975.

- The complete sequences of both the plus and minus strand of the 76-3 insert were determined. The forward primer (S1→) (corresponding with nucleotides 209 to 224), reverse primer (←S2) (annealing to nucleotides 255 to 271) and the plasmid-specific T3  
25 (T3→) and T7 (← T7) primers (insert-specific primer sequences, or their annealing sites, are underlined) are shown in Figure 1. P1→ and P2 ← denote the primer sites used in the RT-PCR experiment.

The sequence obtained by N-terminal sequencing of the rTdPI protein is in bold italics in Figure 1. The wave denotes a heparin-binding consensus sequence. The double line indicates a putative glycosylation site. The polyadenylation signal and the polyA-tail are shown in bold letter type. The leucine indicated by the asterisks is a methionine in clones 5 76, 76-1 and 76-2.

Sequence data were analysed using the GCG sequence analysis software [Genetics-Computer-Group, 1994 #14]. Protein database searches were done at the National Centre for Biotechnology Information (NCBI) using the BLAST network service (Altschul *et al.*, 1990).

10 Once clone 76 was sequenced, the library was rescreened for additional clones by DNA hybridization of plaque lifts (Sambrook, Fritsch & Maniatis, 1989). The probe used was constructed by random primer labelling of the original cDNA (excised from purified plasmid using *EcoRI* and *Eco0109I*) with digoxigenin (Boehringer Mannheim). Three positive clones were isolated and sequenced.

#### 15 **Recombinant protein expression**

Recombinant TdPI (rTdPI) was expressed as a histidine-tagged protein in *Spodoptera frugiperda* ovarian cells (*Sf21*; Invitrogen). The coding region of the TdPI cDNA was amplified by the polymerase chain reaction (PCR), using the forward primer

5'-GCAGGAGCTCGGCACGAG

20 and the reverse primer

5'-TATGGATCCCAGGTCCAGGCTCTGTTCCG,

thereby adding a *Sac* I site upstream of the start codon, and replacing the stop codon with a *Bam* HI site. The PCR consisted of 20 cycles with a 30-second melting step (95°C), a 30-second primer-annealing step (50°C) and a 30-second extension step (72°C). The PCR 25 product was ligated between the *Sac* I and *Bam* HI sites of the pAC129.1 transfer vector (Livingstone & Jones, 1989), which was modified so that a carboxyterminal Gly-Ile-(His)<sub>6</sub> tag was added to the expressed protein. Co-transfection of *Sf21* cells with the transfer vector and baculovirus (BacPak6) and amplification of recombinant virus was as described



by Kitts & Possee, 1993. rTdPI was expressed in TC100 medium (Gibco BRL) containing 10% foetal bovine serum (Sigma).

### Recombinant protein purification

Sixty hours after infection of the S/21 cells, the culture medium was collected and rTdPI was precipitated by addition of  $(\text{NH}_4)_2\text{SO}_4$  (30 g per 100 ml medium). The pellet was redissolved in 50 mM sodium phosphate buffer (pH 8) containing 300 mM NaCl and 10% glycerol. rTdPI was purified using a Ni-NTA agarose (Qiagen) column, mainly according to Janknecht *et al.*, 1991. 50 mM sodium phosphate buffer (pH 6.5) containing 300 mM NaCl and 10% glycerol was used to wash the column. The histidine-tagged protein was eluted using 200 mM imidazole in 75 mM  $\text{NaH}_2\text{PO}_4$ . Further purification was obtained by low pressure chromatography using the BioLogic system (Bio-Rad) with a HiTrap SP cation exchange column (Pharmacia Biotech). The running buffer was 50 mM Hepes, pH 8, with a linear 0 to 250 mM NaCl gradient over 1 hour; the flow rate was 1 ml/min. Centricon 3 concentrators (Amicon) were used for concentration of the eluants and for buffer exchange. The purified protein was stored at  $-20^\circ\text{C}$  in PBS until use. Protein concentration was measured using the Bio-Rad Protein Assay and the Micro BCA Protein Assay (Pierce).

### Protein electrophoresis

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was according to Laemmli, 1970.

Figure 2 shows a 15% SDS-polyacrylamide gel showing rTdPI, purified by means of metal-affinity chromatography and cation exchange. The protein in lane A had been treated with PNGase F (the ~35 kDa protein on the gel) prior to electrophoresis. Lane B contains untreated rTdPI. The molecular masses are given in kDa. Lane C contains unreduced rTdPI (no reducing agent in the loading buffer). The higher molecular weight at which unreduced rTdPI runs would normally suggest dimerization through intermolecular disulphide bridges, but mass-spectrometry places the molecular mass at about 13,500 Da, contradicting the formation of dimers.

Asparagine-linked glycosylation was studied by treating rTdPI with N-glycosidase F (PNGase F; New England BioLabs), followed by SDS-PAGE. PNGase F hydrolyses all common types of Asn-glycan chains from glycoproteins (Maley *et al.*, 1989).

Figure 3 shows an alignment of TdPI with Kunitz domains of the bovine colostrum trypsin inhibitor (BovCol; Cechova, 1976), (bovine) aprotinin (Creighton & Charles, 1987), and the rat tissue factor pathway inhibitor (TFPI-2; only the second, factor Xa-inhibiting domain is shown; Enjyoji *et al.*, 1992). The Kunitz domains of the tick anticoagulant peptide TAP (Waxman *et al.*, 1990) and the two domains in ornithodorin (ornith1 and ornith2; Van de Locht *et al.*, 1996) are also included. The alignment of TdPI with the vertebrate Kunitz domains was created using GCG's "pileup" and "prettyplot" commands, choosing relatively low gap and length weights (1 and 0.03, respectively). The alignment was then modified, mainly by introducing extra gaps, so that the TAP and ornithodorin domains could be included. The modification was largely based on the alignment of the latter domains with aprotinin, as reported by Van de Locht *et al.*, 1996. The arrow indicates the P1 residue of the aprotinin binding loop. The asterisks denote the cysteines involved in disulphide-bridge formation in traditional Kunitzdomains.

### N-terminal sequencing

The amino-terminal sequence of rTdPI was determined at the MRC Immunochemistry Unit of the Department of Biochemistry of the University of Oxford, according to Matsudaira, 1987. Electrobotted samples were run on an Applied Biosystems 494A 'Procise' protein sequencer (Perkin-Elmer) using an Applied Biosystems 'Mini-Blott' cartridge.

### Mass Spectrometry

ESI-MS was performed on a VG BioQ triple quadrupole atmospheric pressure mass spectrometer equipped with an electrospray interface operating in positive ion mode. The instrument was calibrated with horse heart myoglobin (7 pmol/μl; average molecular mass 16,951.48 Da).

### Protease inhibition assays

Elastase (type I, from porcine pancreas),  $\alpha$ -chymotrypsin, trypsin, thrombin, plasmin, tissue kallikrein, plasma kallikrein, urokinase, aprotinin, n-succinyl-Ala-Ala-Ala-p-nitroanilide, Gly-Arg-p-nitroanilide, n- $\alpha$ -benzoyl-DL-Arg-p-nitroanilide and n-benzoyl-Pro-Phe-Arg-p-nitroanilide were purchased from Sigma. Factor Xa and recombinant human tryptase were from Promega and resorufin-labelled casein, soybean trypsin inhibitor, Chromozym TH and Chromozym X were obtained from Boehringer Mannheim.

Tryptase activity was measured in 96-well microplates, using n- $\alpha$ -benzoyl-DL-Arg-p-nitroanilide as chromogenic substrate and 50 mM HEPES pH 7.6, containing 120 mM NaCl, as reaction buffer. 50  $\mu$ l buffer containing 1  $\mu$ l of the tryptase stock (200  $\mu$ g/ml) was combined with 50  $\mu$ l of inhibitor solution (various concentrations). After a 45-minute incubation period at 37  $^{\circ}$ C, 50  $\mu$ l of 3 mM substrate solution was added and the increase in absorbance at 405 nm was measured using a Titertek Multiskan Plus MKII plate reader (ICN).

Other proteases were preincubated with various amounts of protease inhibitor in a total volume of 100  $\mu$ l protease buffer (20 minutes; 37  $^{\circ}$ C). The residual protease activity was determined by adding the appropriate substrates (in 900  $\mu$ l protease buffer) and measuring the degree of digestion. Trypsin,  $\alpha$ -chymotrypsin, and elastase activities were measured in protease buffer A (0.1 M Tris.HCl, 10 % glycerol, 10 mM  $\text{CaCl}_2$ , pH 8); plasmin, urokinase, kallikrein,  $\alpha$ -thrombin and factor Xa activities were determined in protease buffer B (50 mM Tris.HCl, 0.1 mg/ml bovine serum albumin, 150 mM NaCl, 1 mM  $\text{CaCl}_2$ , pH 8), as described by Nakamura *et al.*, 1987. Resorufin-labelled casein was used as a substrate for trypsin,  $\alpha$ -chymotrypsin and plasmin, and the amount of released peptide was measured to determine protease activity (Twining, 1984). p-Nitroanilide (pNA)-substrates were used for elastase, kallikrein, urokinase,  $\alpha$ -thrombin and factor Xa activities (n-succinyl-Ala-Ala-Ala-pNA, n-benzoyl-Pro-Phe-Arg-pNA, Gly-Arg-pNA, Chromozym TH, and Chromozym X, respectively); protease activity was measured by determining the increase in absorbance at 410 nm.

Figure 4 shows a diagram showing the relatively weak inhibitory activity of rTdPI on tissue kallikrein. The absorbance at 410 nm is shown at different time points after addition of

30µg substrate (n-benzoyl-Pro-Phe-Arg-pNA) to kallikrein/antiprotease samples. 0.5 u/ml tissue kallikrein was used per sample (1 ml final volume). The full line (◆—◆) denotes kallikrein activity in the absence of protease inhibitor. Aprotinin used at a concentration of 0.75µM completely inhibits kallikrein activity (●—●). A ten times higher concentration of rTdPI [7.5 µM (O—O)] barely inhibits 50% of the kallikrein activity. Other concentrations of rTdPI used in the experiment were 3.75 µM (Δ—Δ) and 0.75 µM (□—□).

Figure 5 shows the activities of plasmin (left) and trypsin (right) in the presence of increasing amounts of rTdPI as determined by measuring peptide release from resorufin-labelled casein. The peptide release in the absence of inhibitor was set to be 100%, hydrolysis in the absence of protease corresponds with 0% activity. The values for rTdPI are denoted by the open circles. To calculate the micromolar concentration of rTdPI monomers from the mg/ml data obtained with the protein assay, both the calculated molecular mass of 12 kDa (O—O ; assuming no binding of Coomassie blue to the carbohydrate fraction of the glycoprotein) and the (average) molecular mass as determined by mass-spectrometry (13.5 kDa; O—O) were used. The concentrations corresponding with a 50% plasmin inhibition are 0.097 µM for aprotinin (Δ—Δ), 0.23 µM for soybean trypsin inhibitor (■—■), 0.32 µM (O—O) and 0.43 µM (O—O) for rTdPI monomers. The values for 50% trypsin inhibition are 0.024 µM (Δ—Δ), 0.026 µM (■—■), 0.033 µM (O—O) and 0.044 µM (O—O).

Figure 6 shows the inhibition of recombinant human tryptase (Promega) with TdPI. Preincubation of recombinant human tryptase with increasing amounts of rTdPI quickly reduces the catalytic activity to about 33% of the activity in the absence of inhibitor ( $V_0$  : the velocity of substrate turnover measured without tryptase present;  $V_i$  : the velocity with inhibitor added).

## Reverse transcriptase-polymerase chain reaction (RT-PCR)

Salivary glands were excised from unfed adult ticks, and from adult ticks that had been feeding on guinea pigs for 2, 4 and 6 days. Each tissue sample consisted of 15 pairs of glands. Total RNA was isolated from these glands using the *RNAce* Total Pure extraction kit (Bioline Ltd) and 1/30 of the amount obtained (the equivalent of one gland) was used as a template for RT-PCR (35 cycles), utilizing the Titan one tube RT-PCR system

(Boehringer Mannheim). RT-PCR was also carried out on pooled RNA from gut, gonads, accessory sex glands and malpighian tubules, taken from 2-days fed adult ticks. Whole-body homogenates of 3 days-fed larvae and 3 days-fed nymphs were submitted to the same procedure; the amount of RNA used per PCR reaction corresponded with the extract from 1 nymph or 2 larvae. The primer sequences (P1 and P2) are underlined in Figure 1. To check whether the RT-PCR products were specifically derived from TdPI mRNA, their sizes were compared to the size of a marker that was obtained by PCR-amplification of the original plasmid DNA, using the same primers.

Figure 7 shows a 1.5% agarose gel showing the RT-PCR products obtained with whole-body extracts from larvae (L) and nymphs (N), and with salivary gland extracts from adult, *R. appendiculatus* males and females. The numbers correspond with different time points of the adult feeding stage; 0 denotes samples taken from unfed ticks; 2, 4 and 6 indicate 2, 4 and 6 days fed ticks, respectively. Lane M shows as a the molecular weight marker tee PCR product obtained with the same set of primers (Fig. 1), but using the TdPI cDNA as a template, instead of RNA.

## REFERENCES

- Alter S.C., Kramps J.A., Janoff A. *et al.* (1990) Interactions of human mast cell tryptase with biological protease inhibitors. *Archives of Biochemistry and Biophysics* **276**, 26-31.
- 5 Altschul S.F., W. G., Miller W. *et al.* (1990) Basic local alignment search tool. *Journal of Molecular Biology* **215**, 403-410.
- Auerswald E.A., Morenweiser R., Sommerhoff C.P. *et al.* (1994) Recombinant leech-derived tryptase inhibitor: construction, production, protein chemical characterization and inhibition of HIV-1 replication. *Biological Chemistry Hoppe-*  
10 *Seyler* **375**, 695-703.
- Ausubel *et al.*, 1991, Current Protocols in Molecular Biology, Wiley Interscience, New York.
- Cechova D. (1976) Trypsin inhibitor from cow colostrum. *Methods in Enzymology* **45**, 806-813.
- 15 Cregar L., Elrod K.C., Putnam D. *et al.* (1999) Neutrophil myeloperoxidase is a potent and selective inhibitor of mast cell tryptase. *Archives of Biochemistry and Biophysics* **366**, 125-130.
- Creighton T.E. & Charles I.G. (1987) Sequences of the genes and polypeptide precursors for two bovine protease inhibitors. *Journal of Molecular Biology* **194**, 11-22.
- 20 Elrod K.C., Moore W.R., Abraham W.M. *et al.* (1997) Lactoferrin, a potent tryptase inhibitor, abolishes late-phase airway responses in allergic sheep. *American Journal of Respiratory and Critical Care Medicine* **156**, 375-381.
- Enjyoji K., Emi M., Mukai T. *et al.* (1992) cDNA cloning and expression of rat tissue factor pathway inhibitor (TFPI). *Journal of Biochemistry (Tokyo)* **111**, 681-687.

- Fernandez J.M. & Hoeffler J.P., eds. (1998) Gene expression systems. Using nature for the art of expression. Academic Press, San Diego, London, Boston, New York, Sydney, Tokyo, Toronto.
- Program Manual for the Wisconsin Package, version 8. , 575 Science Drive, Madison,  
5 Wisconsin, USA 53711.
- Goode B.L. & Feinstein S.C. (1992) "Speedprep" purification of template for double-stranded DNA-sequencing. *BioTechniques* **12**, 374-375.
- Janknecht R., de Martynoff G., Lou L. *et al.* (1991) Rapid and efficient purification of native histidine-tagged protein expressed by recombinant vaccinia virus.  
10 *Proceedings of the National Academy of Sciences USA* **88**, 8972-8976.
- Jones L.D., Davies C.R., Steele G.M. *et al.* (1988) The rearing and maintenance of ixodid and argasid ticks in the laboratory. *Animal Technology* **39**, 99-106.
- Kitts P.A. & Possee R.D. (1993) A method for producing recombinant baculovirus expression vectors at high frequency. *BioTechniques* **14**, 810-817.
- 15 Laemmli V.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* **227**, 680-685.
- Leon *et al.*, (1994) *P.N.A.S.USA* **91**: 3739-3743.
- Liang *et al.*, (1998) *J. Cutaneous Pathology* **25**: 189-198.
- Livingstone C. & Jones I. (1989) Baculovirus expression vectors with single strand  
20 capability. *Nucleic Acids Research* **17**, 2366.
- Maley F., Trimble R.B., Tarentino A.L. *et al.* (1989) Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. *Analytical Biochemistry* **180**, 195-204.
- Matsudaira P. (1987) Sequence from picomole quantities of proteins electroblotted onto  
25 polyvinylidene difluoride membranes. *Journal of Biological Chemistry* **262**, 10035-10038.

- Mierendorf R.C. & Pfeffer D. (1987) Direct sequencing of denatured plasmid DNA. *Methods in Enzymology* **152**, 556-562.
- Mühlhahn P., Czisch M., Morenweiser R. *et al.* (1994) Structure of leech derived tryptase inhibitor (LDTI-C) in solution. *FEBS Letters* **355**, 290-296.
- 5 Nakamura T., Hirai T., Tokunaga F. *et al.* (1987) Purification and amino-acid sequence of kunitz-type protease inhibitor found in hemocytes of horseshoe crab (*Tachypleus tridentatus*). *Journal of Biochemistry (Tokyo)* **101**, 1297-1306.
- Paesen G.C. & Nuttall P.A. (1996) A tick homologue of the human Ki nuclear autoantigen. *Biochimica et Biophysica Acta* **1309**, 9-13.
- 10 Pohlig G., Fendrich G., Knecht R. *et al.* (1996) Purification, characterization and biological evaluation of recombinant leech-derived tryptase inhibitor (rLDTI) expressed at high level in the yeast *Saccharomyces cerevisiae*. *European Journal of Biochemistry* **241**, 619-626.
- Sambrook J., Fritsch E.F. & Maniatis T. (1989) *Molecular cloning : a laboratory manual*.  
15 pp. Pages. New York: Cold Spring Harbor Laboratory Press
- Sanger F. & Coulson A.R. (1975) A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. *Journal of Molecular Biology* **94**, 441-448.
- Schwartz L.B. (1994) Tryptase: a mast cell serine protease. *Methods in Enzymology* **244**, 88-100.
- 20 Short J.M., Fernandez J.M., Sorge J.A. *et al.* (1988) Lambda-ZAP: a bacteriophage lambda expression vector with in vivo excision properties. *Nucleic Acids Research* **16**, 7583-7600.
- Sommerhoff C.P., Söllner C., Mentele R. *et al.* (1994) A Kazal-type inhibitor of human mast cell tryptase: isolation from the medical leech *Hirudo medicinalis*,  
25 characterization, and sequence analysis. *Biological Chemistry Hoppe-Seyler* **375**, 685-694.
- Spector, *et al.*, 1998, Cells, a laboratory manual; Cold Spring Harbor Laboratory Press., New York.



- Stubbs M.T., Morenweiser R., Stürzebecher J. *et al.* (1997) The three-dimensional structure of recombinant leech-derived tryptase inhibitor in complex with trypsin. Implications for the structure of human mast cell tryptase and its inhibition. *Journal of Biological Chemistry* **272**, 19931-19937.
- 5 Towbin *et al.*, (1979) *P.N.A.S. USA* **76**: 4350-4354.
- Twining S.S. (1984) Fluorescein isothiocyanate-labeled casein assay for proteolytic enzymes. *Analytical Biochemistry* **143**, 30-34.
- Van de Locht A., Stubbs M.T., Bode W. *et al.* (1996) The ornithodorin-thrombin crystal structure, a key to the TAP enigma? *EMBO Journal* **15**, 6011-6017.
- 10 Waxman L., Smith D.E., Arcuri K.E. *et al.* (1990) Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. *Science* **248**, 593-596.

### Claims

1. A recombinant protein that exhibits significant sequence homology with the tick-derived protease inhibitor protein (TdPI) sequence given in Figure 1, an active fragment of said protein or a functional equivalent of said protein.
- 5 2. A recombinant protein, protein fragment or functional equivalent according to claim 1, that functions as an inhibitor of tryptase, preferably of human mast cell tryptase.
3. A recombinant protein, protein fragment or functional equivalent according to either of claims 1-2 that contains one or more epitopes that can be used in the development of vaccines that target proteins that exhibit significant sequence homology with TdPI.
- 10 4. A recombinant protein or protein fragment according to claim 1, wherein said sequence homology is defined as 50% or more of the amino acids in the sequence being completely conserved as identical residues if the protein is aligned with the sequence of Figure 1, the alignments being obtained using GCG's bestfit command (gap creation penalty = 2.5; gap extension penalty = 0.5).
- 15 5. A recombinant protein or protein fragment according to claim 4, wherein said sequence homology is 60% or more.
6. A recombinant protein or protein fragment according to claim 5, wherein said sequence homology is 75% or more.
7. A recombinant protein or protein fragment according to any one of claims 1-6
- 20 comprising the TdPI sequence.
8. A recombinant protein derived from a blood-feeding arthropod ectoparasite that inhibits tryptase, or an active fragment of said protein or a functional equivalent of said protein.
9. A recombinant protein, protein fragment or functional equivalent according to claim 8,
- 25 that functions as an inhibitor of tryptase, preferably of human mast cell tryptase.

10. A recombinant protein, protein fragment or functional equivalent according to claim 8 or claim 9 that contains one or more epitopes that can be used in the development of vaccines that target proteins that exhibit significant sequence homology with TdPI.
11. A recombinant protein or protein fragment according to any one of claims 1-10 that  
5 inhibits tryptase with a  $K_i$  of less than  $1 \times 10^{-6}$  M, preferably less than  $1 \times 10^{-7}$  M, more preferably less than  $2 \times 10^{-8}$  M, most preferably less than  $1 \times 10^{-9}$  M.
12. A recombinant protein, protein fragment or functional equivalent according to any one of the claims 1-11 that inhibits catalytic tryptase activity.
13. A recombinant protein, protein fragment or functional equivalent according to any one  
10 of claims 1-12 which inhibits mast cell tryptase, preferably human mast cell tryptase.
14. A recombinant protein, protein fragment or functional equivalent according to any one of the preceding claims, that is derived from a tick.
15. A recombinant protein, protein fragment or functional equivalent according to claim 14, that is derived from the tick *Rhipicephalus appendiculatus*.
- 15 16. A recombinant protein, protein fragment or functional equivalent according to any one of the preceding claims that has been genetically or chemically fused to one or more peptides or polypeptides.
17. A recombinant protein, protein fragment or functional equivalent according to any one of the preceding claims that is bound to a support, such as a resin.
- 20 18. A pharmaceutical composition comprising a recombinant protein, protein fragment or functional equivalent according to any one of claims 1-17, in conjunction with a pharmaceutically-acceptable carrier.
19. A vaccine composition comprising a recombinant protein, protein fragment or  
25 functional equivalent according to any one of claims 1-15, optionally in conjunction with an adjuvant.
20. A process for the formulation of a pharmaceutical composition according to claim 19 comprising bringing a recombinant protein, protein fragment or functional equivalent

according to any one of claims 1-15 into association with a pharmaceutically-acceptable carrier.

21. A recombinant protein, protein fragment or functional equivalent according to any one of claims 1 to 15 for use as a pharmaceutical.
- 5 22. A method for the prevention or treatment of a disease in a subject, comprising administering to said subject an effective dose of a composition according to claim 18 or claim 19.
23. A nucleic acid molecule encoding a recombinant protein, protein fragment or functional equivalent according to any one of claims 1-16.
- 10 24. A nucleic acid molecule: having the sequence given in Figure 1; which hybridises with said nucleotide sequence under stringent hybridisation conditions; or which encodes on expression a recombinant protein, protein fragment or functional equivalent as defined in any one of claims 1-16.
25. A vector comprising a nucleic acid according to claim 23 or claim 24.
- 15 26. The vector of claim 25 that is virus-based.
27. A host cell transformed or transfected with the vector of claim 25 or claim 26.
28. A transgenic animal that has been transformed by a nucleic acid molecule according to claim 23 or claim 24.
29. A method of preparing a recombinant protein, protein fragment or functional  
20 equivalent according to any one of claims 1 to 16, comprising expressing a vector according to claim 25 or claim 26 in a host cell and culturing said host cell under conditions where said recombinant protein, protein fragment or functional equivalent is expressed, and recovering said recombinant protein, protein fragment or functional equivalent thus produced.
- 25 30. Use of a recombinant protein, protein fragment or functional equivalent according to any one of claims 1-17 for: the detection or quantification of tryptase; for the depletion or removal of tryptase from a food product or from a cell culture; as an anti-tryptase agent; or as an anti-inflammatory drug.

31. Use of a recombinant protein, protein fragment or functional equivalent according to any one of claims 1 to 16 in the manufacture of a medicament for the treatment of inflammation in humans or animals.
32. A method of vaccinating a mammal against a disease, or of treating a mammal suffering from a disease, comprising administering a recombinant protein, protein fragment or functional equivalent according to any one of claims 1 to 16 to a said mammal.
33. Use of a protein or protein fragment selected from the group consisting of bovine colostrum trypsin inhibitor, the rat tissue factor pathway inhibitor (TFPI-2), the Kunitz domain of the tick anticoagulant peptide TAP and the two domains in ornithodorin as a tryptase inhibitor.

10/031685

**1/6**

**FIG. 1**

T3 →

GAAACCTCATGGCGCCGCACTACCCCTAATCGTCGCCCATCGTGTGGCTTTCGTTGCAAGCACACTAGG  
M G R T T L I V A I V L V A F V A S T L G

✱

**P1→**

AAATGCCCTACCCTAAAGTGGAAGAAGACGTAAACAGGCCTAATTGGGATTTGGGAAAAGGAAGAG  
N A Y P K V E E R R N R P N W D F G K R K E E

TGTACCGTTCCCTATTGGTTGGAGCGCAACCAGTAAAGGGCTTTGCAAGGCTAGATTTACTAGGTATTACT  
 C T V P I G W S E P V K G L C K A R F T R Y Y C

↑ 15

→ S2

GCATGGGGAACTGTTGCAAGGTATACGAAGGCTGCTACACAGGAGGCTATTCCAGAATGGGTGAATGCCG  
M G N C C K V Y E G C Y T G G Y S R M G E C A

←P2

GAGAAATTGTCCCGCTTCAAAGACCGACACAGGGTTCAGACCACGGCAGGACTAGAGAACGGAACA  
R N C P G F K R P T P G F R P R H G L E N G T

E P G P \*  
GAGCCTGGACCTTGAAACCTCAGATAATAATTCTCGAAGACCTCGATTATTTCACCATGAGGCCGTTT 420

← I7

TTT TTT CCA ATA AAG CGG CAA GGA CAT CAT CTA CTG AAA TAAA ATA AGA AAC CAAAA AAAA 490

2/6

FIG. 2





FIG. 7



10/031685


FIG. 3

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--



4/6

FIG. 4



5/6






FIG. 5



6/6



**DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below under my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

**INHIBITOR PROTEINS**

the Specification of which

☐ is attached hereto

☒ was filed on 19 July 2000

as International Application No. PCT/GB00/02791

I hereby state that I have reviewed and understand the contents of the above-identified Specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 (a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

<u>APPLICATION</u> <u>NUMBER</u>	<u>PRIOR FOREIGN FILED APPLICATION(S)</u> <u>COUNTRY</u>	<u>(MONTH/DAY/YYYY)</u>	<u>PRIORITY</u> <u>CLAIMED</u>
9916913.8	Great Britain	July 19, 1999	YES

I hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER(S)

FILING DATE (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent <u>Application No.</u>	PCT Parent <u>Number</u>	Parent Filing <u>(MM/DD/YYYY)</u>	Parent Patent <u>Number (if applicable)</u>
---------------------------------------	-----------------------------	--------------------------------------	--

The undersigned hereby authorizes the U.S. attorney or agent named herein to accept and follow instructions from **CARPMAELS & RANSFORD** as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between the U.S. attorney or agent and the undersigned. In the event of a change in the persons from whom instructions may be taken, the U.S. attorney or agent named herein will be so notified by the undersigned.

I hereby appoint as my attorneys or agents the registered persons identified under

**Customer No. 23565**

for the law firm of Klauber & Jackson, said attorneys or agents with full power of substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Please address all correspondence regarding this application to **Customer No. 23565**.

DAVID A. JACKSON, ESQ.  
KLAUBER & JACKSON  
411 HACKENSACK AVENUE  
HACKENSACK, NEW JERSEY 07601

Direct all telephone calls to David A. Jackson at (201) 487-5800.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00  
FULL NAME OF FIRST OR SOLE INVENTOR: Patricia Anne NUTTALL

COUNTRY OF CITIZENSHIP: Great Britain

FULL RESIDENCE ADDRESS: 1 Manor Farm  
Culham  
Oxon OX14 4NP  
United Kingdom

GBX

FULL POST OFFICE ADDRESS: SAME AS ABOVE

SIGNATURE OF INVENTOR PAN Nuttall

DATE 15/02/02

2-00  
FULL NAME OF SECOND INVENTOR: Guido Christiaan PAESEN

COUNTRY OF CITIZENSHIP: BELGIUM

FULL RESIDENCE ADDRESS: Guy Court  
Flat 2  
1 King Street  
Jericho, Oxford OX2 6DB  
United Kingdom

GBX

FULL POST OFFICE ADDRESS: SAME AS ABOVE

SIGNATURE OF INVENTOR Guido Christiaan Paesen

DATE 15/02/02